Skip to main content
SpringerLink
Log in
Book cover

Complement Therapeutics pp 1–22Cite as

Progress and Trends in Complement Therapeutics

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 735))

Abstract

The past few years have proven to be a highly successful and exciting period for the field of complement-directed drug discovery and development. Driven by promising experiences with the first marketed complement drugs, increased knowledge about the involvement of complement in health and disease, and improvements in structural and analytical techniques as well as animal models of disease, the field has seen a surge in creative approaches to therapeutically intervene at various stages of the cascade. An impressive panel of compounds that show promise in clinical trials is meanwhile being lined up in the pipelines of both small biotechnology and big pharmaceutical companies. Yet with this new focus on complement-targeted therapeutics, important questions concerning target selection, point and length of intervention, safety, and drug delivery emerge. In view of the diversity of the clinical disorders involving abnormal complement activity or regulation, which include both acute and chronic diseases and affect a wide range of organs, diverse yet specifically tailored therapeutic approaches may be needed to shift complement back into balance. This chapter highlights the key changes in the field that shape our current perception of complement-targeted drugs and provides a brief overview of recent strategies and emerging trends. Selected examples of complement-related diseases and inhibitor classes are highlighted to illustrate the diversity and creativity in field.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Ahmad M, Pyaram K, Mullick J, Sahu A (2007) Viral complement regulators: the expert mimicking swindlers. Indian J Biochem Biophys 44(5):331–343

    CAS  PubMed  Google Scholar 

  • Alcorlo M, Martinez-Barricarte R, Fernandez FJ, Rodriguez-Gallego C, Round A, Vega MC et al (2011) Unique structure of iC3b resolved at a resolution of 24 A by 3D-electron microscopy. Proc Natl Acad Sci USA 108(32):13236–13240

    Article  PubMed  PubMed Central  Google Scholar 

  • Alexion (2011) Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS). Alexion Pharmaceuticals Press Release

    Google Scholar 

  • Alfinito F, Ruggiero G, Sica M, Udhayachandran A, Rubino V, Pepa RD et al (2011) Eculizumab treatment modifies the immune profile of PNH patients. Immunobiology 217(7):698–703

    Article  CAS  PubMed  Google Scholar 

  • Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185(9):5628–5636

    Article  CAS  PubMed  Google Scholar 

  • Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR et al (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95–112

    Article  CAS  PubMed  Google Scholar 

  • Arlaud GJ, Barlow PN, Gaboriaud C, Gros P, Narayana SV (2007) Deciphering complement mechanisms: the contributions of structural biology. Mol Immunol 44(16):3809–3822

    Article  CAS  PubMed  Google Scholar 

  • Asgari E, Zhou W, Sacks S (2010) Complement in organ transplantation. Curr Opin Organ Transplant 15(4):486–491

    Article  PubMed  Google Scholar 

  • Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL et al (2009) Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 183(9):5928–5937

    Article  CAS  PubMed  Google Scholar 

  • Banz Y, Rieben R (2012) Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 44(3):205–217

    Article  CAS  PubMed  Google Scholar 

  • Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P et al (2007) Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 76(3):482–493

    Article  CAS  PubMed  Google Scholar 

  • Barratt-Due A, Thorgersen EB, Lindstad JK, Pharo A, Lissina O, Lambris JD et al (2011) Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J Immunol 187(9):4913–4919

    Article  CAS  PubMed  Google Scholar 

  • Beinrohr L, Dobo J, Zavodszky P, Gal P (2008) C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends Mol Med 14(12):511–521

    Article  CAS  PubMed  Google Scholar 

  • Berger J (1974) Complement deposition in the kidney. Adv Nephrol Necker Hosp 4:37–48

    CAS  PubMed  Google Scholar 

  • Blonder J, Issaq HJ, Veenstra TD (2011) Proteomic biomarker discovery: it’s more than just mass spectrometry. Electrophoresis 32(13):1541–1548

    CAS  PubMed  Google Scholar 

  • Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, Tytarenko RG et al (2010) Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285(44):33826–33833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bosmann M, Ward PA (2012) Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 946:147–159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brodbeck RM, Cortright DN, Kieltyka AP, Yu J, Baltazar CO, Buck ME et al (2008) Idenepsication and characterization of NDT 9513727 [N, N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanam ine], a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther 327(3):898–909

    Article  CAS  PubMed  Google Scholar 

  • Brown KM, Sacks SH, Sheerin NS (2007) Mechanisms of disease: the complement system in renal injury – new ways of looking at an old foe. Nat Clin Pract Nephrol 3(5):277–286

    Article  CAS  PubMed  Google Scholar 

  • Carroll MV, Sim RB (2011) Complement in health and disease. Adv Drug Deliv Rev 63(12):965–975

    Article  CAS  PubMed  Google Scholar 

  • Cashman SM, Ramo K, Kumar-Singh R (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 6(4):e19078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chavakis T, Preissner KT, Herrmann M (2007) The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol 28(9):408–418

    Article  CAS  PubMed  Google Scholar 

  • Chen Song S, Zhong S, Xiang Y, Li JH, Guo H, Wang WY et al (2011) Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 11(10):2057–2066

    Article  CAS  PubMed  Google Scholar 

  • Chen H, Ricklin D, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G et al (2010) Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA 107(41):17621–17626

    Article  PubMed  PubMed Central  Google Scholar 

  • Chi ZL, Yoshida T, Lambris JD, Iwata T (2010) Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol 703:127–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christiansen D, Brekke OL, Stenvik J, Lambris JD, Espevik T, Mollnes TE (2012) Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Adv Exp Med Biol 946:237–251

    Article  CAS  PubMed  Google Scholar 

  • Davis AE 3rd, Lu F, Mejia P (2010) C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104(5):886–893

    CAS  PubMed  Google Scholar 

  • Degn SE, Jensenius JC, Thiel S (2011) Disease-causing mutations in genes of the complement system. Am J Hum Gen 88(6):689–705

    CAS  PubMed  Google Scholar 

  • Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R (2008) FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13(9):993–1000

    Article  CAS  PubMed  Google Scholar 

  • Ekdahl KN, Lambris JD, Elwing H, Ricklin D, Nilsson PH, Teramura Y et al (2011) Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv Rev 63(12):1042–1050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Engstrom G, Hedblad B, Janzon L, Lindgarde F (2007) Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 14(3):392–397

    Article  PubMed  Google Scholar 

  • Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM et al (2009) Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer’s disease. J Immunol 183(2):1375–1383

    Article  CAS  PubMed  Google Scholar 

  • Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y et al (2011) Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer’s disease. J Neuroinflammation 8(1):4

    Article  PubMed  PubMed Central  Google Scholar 

  • Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD et al (2010) Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330(6012):1816–1820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fraser DA, Harris CL, Williams AS, Mizuno M, Gallagher S, Smith RA et al (2003) Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 278(49):48921–48927

    Article  CAS  PubMed  Google Scholar 

  • Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, Horvath CJ et al (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118(17):4705–4713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fritzinger DC, Dean R, Meschter C, Wong K, Halter R, Borlak J et al (2010) Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv Exp Med Biol 703:151–162

    Article  CAS  PubMed  Google Scholar 

  • Fujita E, Farkas I, Campbell W, Baranyi L, Okada H, Okada N (2004) Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a. J Immunol 172(10):6382–6387

    Article  CAS  PubMed  Google Scholar 

  • Fujiwara I, Nakajima H, Akioka K, Matsuda T, Oka T (1997) Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection. Transplant Proc 29(1–2):935–937

    Article  CAS  PubMed  Google Scholar 

  • Garlatti V, Chouquet A, Lunardi T, Vives R, Paidassi H, Lortat-Jacob H et al (2010) Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J Immunol 185(2):808–812

    Article  CAS  PubMed  Google Scholar 

  • Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X et al (2011) rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 17(21):6702–6711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S et al (2010) Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10(8):922–931

    Article  CAS  PubMed  Google Scholar 

  • Ghebremariam YT, Engelbrecht G, Tyler M, Lotz Z, Govender D, Kotwal GJ et al (2010) Vaccinia virus complement control protein (VCP) improves kidney structure and function following ischemia/reperfusion injury in rats. J Surg Res 159(2):747–754

    Article  CAS  PubMed  Google Scholar 

  • Gibson J, Hakobyan S, Cree AJ, Collins A, Harris CL, Ennis S et al (2012) Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiology 217(2):251–255

    Article  CAS  PubMed  Google Scholar 

  • Gingras AR, Girija UV, Keeble AH, Panchal R, Mitchell DA, Moody PC et al (2011) Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure 19(11):1635–1643

    Article  CAS  PubMed  Google Scholar 

  • Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e15004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gombos T, Forhecz Z, Pozsonyi Z, Szeplaki G, Kunde J, Fust G et al (2012) Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin Res Cardiol. doi:10.1007/s00392-012-0432-6

    Google Scholar 

  • Gompels MM, Lock RJ (2011) Cinryze (C1-inhibitor) for the treatment of hereditary angioedema. Expert Rev Clin Immunol 7(5):569–573

    Article  CAS  PubMed  Google Scholar 

  • Gustafsson E, Forsberg C, Haraldsson K, Lindman S, Ljung L, Furebring C (2009) Purification of truncated and mutated chemotaxis inhibitory protein of Staphylococcus aureus – an anti-inflammatory protein. Protein Expr Purif 63(2):95–101

    Article  CAS  PubMed  Google Scholar 

  • Hadders MA, Bubeck D, Roversi P, Hakobyan S, Forneris F, Morgan BP et al (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1:1–8

    Article  CAS  Google Scholar 

  • Halili MA, Ruiz-Gomez G, Le GT, Abbenante G, Fairlie DP (2009) Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation. Biochemistry 48(35):8466–8472

    Article  CAS  PubMed  Google Scholar 

  • Hamilton G, Evans KL, Macintyre DJ, Deary IJ, Dominiczak A, Smith BH et al (2012) Alzheimer’s disease risk factor complement receptor 1 is associated with depression. Neurosci Lett 510(1):6–9

    Article  CAS  PubMed  Google Scholar 

  • Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL et al (2010) Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 19(1):209–215

    Article  CAS  PubMed  Google Scholar 

  • Hepburn NJ, Williams AS, Nunn MA, Chamberlain-Banoub JC, Hamer J, Morgan BP et al (2007) In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 282(11):8292–8299

    Article  CAS  PubMed  Google Scholar 

  • Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP et al (2011) Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 108(21):8761–8766

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S (2008) A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 181(11):8068–8076

    Article  CAS  PubMed  Google Scholar 

  • Igonin AA, Protsenko DN, Galstyan GM, Vlasenko AV, Khachatryan NN, Nekhaev IV et al (2011) C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med 40:770–777

    Article  CAS  Google Scholar 

  • Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, Nilsson-Ekdahl K et al (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437(7058):505–511

    Article  CAS  PubMed  Google Scholar 

  • Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444(7116):213–216

    Article  CAS  PubMed  Google Scholar 

  • Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE et al (2011) Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci USA 108(7):2897–2902

    Article  PubMed  PubMed Central  Google Scholar 

  • Kato M, Morozumi K, Takeuchi O, Oikawa T, Koyama K, Usami T et al (2003) Complement fragment C4d deposition in peritubular capillaries in acute humoral rejection after ABO blood group-incompatible human kidney transplantation. Transplantation 75(5):663–665

    Article  CAS  PubMed  Google Scholar 

  • Keating GM (2009) Human C1-esterase inhibitor concentrate (Berinert). BioDrugs 23(6):399–406

    Article  CAS  PubMed  Google Scholar 

  • Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C et al (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res 109(11):1290–1301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kirschfink M, Mollnes TE (2001) C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2(7):1073–1083

    Article  CAS  PubMed  Google Scholar 

  • Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46(14):2753–2766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kocsis A, Kekesi KA, Szasz R, Vegh BM, Balczer J, Dobo J et al (2010) Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation. J Immunol 185(7):4169–4178

    Article  CAS  PubMed  Google Scholar 

  • Kohl J (2006) Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther 8(6):529–538

    CAS  PubMed  Google Scholar 

  • Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD (2011) Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model. Vaccine 29(35):5904–5910

    Article  CAS  PubMed  Google Scholar 

  • Kourtzelis I, Markiewski MM, Doumas M, Rafail S, Kambas K, Mitroulis I et al (2010) Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116(4):631–639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR et al (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6(10):e26332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kulkarni AP, Govender DA, Kotwal GJ, Kellaway LA (2011) Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer’s disease. Curr Alzheimer Res 8(1):95–113

    Article  CAS  PubMed  Google Scholar 

  • Laarman A, Milder F, van Strijp J, Rooijakkers S (2010) Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J Mol Med (Berlin) 88(2):115–120

    Article  CAS  Google Scholar 

  • Lachmann PJ, Smith RA (2009) Taking complement to the clinic – has the time finally come? Scand J Immunol 69(6):471–478

    Article  CAS  PubMed  Google Scholar 

  • Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al (2009) Genome-wide association study idenepsies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41(10):1094–1099

    Article  CAS  PubMed  Google Scholar 

  • Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. Nat Rev Microbiol 6(2):132–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M et al. (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364(26):2561–2563

    Article  CAS  Google Scholar 

  • Laursen L (2011) E. coli crisis opens door for Alexion drug trial. Nat Biotechnol 29(8):671

    Article  PubMed  PubMed Central  Google Scholar 

  • Laursen NS, Gordon N, Hermans S, Lorenz N, Jackson N, Wines B et al (2010) Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci USA 107(8):3681–3686

    Article  PubMed  PubMed Central  Google Scholar 

  • Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR (2011) Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J 30(3):606–616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lazar HL, Keilani T, Fitzgerald CA, Shapira OM, Hunter CT, Shemin RJ et al (2007) Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 116(11 Suppl):I83–I88

    CAS  PubMed  Google Scholar 

  • Lewis AG, Kohl G, Ma Q, Devarajan P, Kohl J (2008) Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 153(1):117–126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li JS, Jaggers J, Anderson PA (2006) The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther 4(5):649–654

    Article  CAS  PubMed  Google Scholar 

  • Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B et al (2005) Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 45(2):415–421

    Article  CAS  PubMed  Google Scholar 

  • Luzzatto L, Risitano AM, Notaro R (2010) Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 95(4):523–526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC et al (2008) Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 199(4):354 e1–8

    Article  CAS  Google Scholar 

  • Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM (2011) Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol 117(1):75–83

    Article  PubMed  PubMed Central  Google Scholar 

  • Markiewski MM, Lambris JD (2009) Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30(6):286–292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9(11):1225–1235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y et al (2005) The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett 100(2):139–145

    Article  CAS  PubMed  Google Scholar 

  • Monk PN, Scola AM, Madala P, Fairlie DP (2007) Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152(4):429–448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP et al (2011) Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 18(4):463–470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mosca T, Menezes MC, Dionigi PC, Stirbulov R, Forte WC (2011) C3 and C4 complement system components as biomarkers in the intermittent atopic asthma diagnosis. J Pediatr (Rio de Janeiro) 87(6):512–516

    Google Scholar 

  • Mullard A (2012) Protein–protein interaction inhibitors get into the groove. Nat Rev Drug Discov 11(3):173–175

    Article  CAS  PubMed  Google Scholar 

  • Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM (1998) X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280(5367):1277–1281

    Article  CAS  PubMed  Google Scholar 

  • Nilsson B, Nilsson UR, Karlsson-Parra A, Sjolin-Forsberg G, Hallgren R (1994) Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome associated with a hereditary C3 dysfunction. Ann Rheum Dis 53(10):691–694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nilsson B, Korsgren O, Lambris JD, Ekdahl KN (2010) Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 31(1):32–38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nunn MA, Sharma A, Paesen GC, Adamson S, Lissina O, Willis AC et al (2005) Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 174(4):2084–2091

    Article  CAS  PubMed  Google Scholar 

  • Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA et al (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360(5):542–544

    Article  PubMed  Google Scholar 

  • Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD (2012) Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol 34(1):151–165

    Article  CAS  PubMed  Google Scholar 

  • Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL et al (2004) C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem 279(1):142–151

    Article  CAS  PubMed  Google Scholar 

  • Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V et al (2007) Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 99(7):890–895

    Article  CAS  PubMed  Google Scholar 

  • Parker CJ (2012) Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 19(3):141–148

    Article  CAS  PubMed  Google Scholar 

  • Patel H, Smith RA, Sacks SH, Zhou W (2006) Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17(4):1102–1111

    Article  CAS  PubMed  Google Scholar 

  • Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH (2002) Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans 30(Pt 6):996–1001

    Article  CAS  PubMed  Google Scholar 

  • Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship TH (2002) Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans 30(Pt 6):996–1001

    Article  CAS  PubMed  Google Scholar 

  • Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M et al (2012) Alzheimer’s disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 33(8):1843.e9-1843.e17

    Article  CAS  PubMed  Google Scholar 

  • Qu H, Ricklin D, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RRG, Lupu F, Barlow PN, Lambris JD (2012) New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (in press). doi:10.1016/j.imbio.2012.06.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Qu H, Ricklin D, Lambris JD (2009) Recent developments in low molecular weight complement inhibitors. Mol Immunol 47(2–3):185–195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ et al (2011) Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol 48(4):481–489

    Article  CAS  PubMed  Google Scholar 

  • Ramos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC et al (2004) Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13(10):777–783

    Article  CAS  PubMed  Google Scholar 

  • Recknagel S, Bindl R, Kurz J, Wehner T, Schoengraf P, Ehrnthaller C et al (2012) C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. J Orthop Res 30(4):581–586

    Article  CAS  PubMed  Google Scholar 

  • Reis SE, Falcao DA, Isaac L (2006) Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 63(3):155–168

    Article  CAS  Google Scholar 

  • Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM (2009) Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50(12):5818–5827

    Article  PubMed  Google Scholar 

  • Ricklin D, Lambris JD (2007a) Complement-targeted therapeutics. Nat Biotechnol 25(11):1265–1275

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ricklin D, Lambris JD (2007b) Exploring the complement interaction network using surface plasmon resonance. Adv Exp Med Biol 598:260–278

    Article  PubMed  Google Scholar 

  • Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273–292

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785–797

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Risitano AM, Perna F, Selleri C (2011) Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev Med Chem 11(6):528–535

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez de Cordoba S, Harris CL, Morgan BP, Llorca O (2011) Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim Biophys Acta 1812(1):12–22

    Article  CAS  PubMed  Google Scholar 

  • Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K et al (2010) A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol 703:137–149

    Article  CAS  PubMed  Google Scholar 

  • Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM (2012) Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther. doi:10.1089/jop.2011.0212

    Google Scholar 

  • Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A et al (2009) Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10(7):721–727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roth A, Hock C, Konik A, Christoph S, Duhrsen U (2011) Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol 93(6):704–714

    Article  CAS  PubMed  Google Scholar 

  • Roversi P, Lissina O, Johnson S, Ahmat N, Paesen GC, Ploss K et al (2007) The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol 369(3):784–793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruiz-Gomez G, Lim J, Halili MA, Le GT, Madala PK, Abbenante G et al (2009) Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem 52(19):6042–6052

    Article  CAS  PubMed  Google Scholar 

  • Sacks SH, Zhou W (2012) The role of complement in the early response to transplantation. Nat Rev Immunol 12(6):431–442

    CAS  PubMed  Google Scholar 

  • Sahu A, Kay BK, Lambris JD (1996) Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 157(2):884–891

    CAS  PubMed  Google Scholar 

  • Sample I (2010) Mirococept could double life of transplant organs. The Guardian 2010. http://www.guardian.co.uk/science/2010/sep/15/mirococept-transplant-organs

  • Sanchez-Carbayo M (2011) Antibody microarrays as tools for biomarker discovery. Methods Mol Biol 785:159–182

    Article  CAS  PubMed  Google Scholar 

  • Schmid RA, Hillinger S, Hamacher J, Stammberger U (2001) TP20 is superior to TP10 in reducing ischemia/reperfusion injury in rat lung grafts. Transplant Proc 33(1–2):948–949

    Article  CAS  PubMed  Google Scholar 

  • Schmidt CQ, Bai H, Risitano AM, Barlow PN, Ricklin D, Lambris JD (2012) Rational engineering of a novel complement regulator affords double targeting of host cells and controls innate immunity in disease condition (submitted)

    Google Scholar 

  • Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F et al (2008) Systemic complement activation in age-related macular degeneration. PLoS One 3(7):e2593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schuster MC, Chen H, Lambris JD (2007) Hydrogen/deuterium exchange mass spectrometry: potential for investigating innate immunity proteins. Adv Exp Med Biol 598:407–417

    Article  PubMed  Google Scholar 

  • Schuster MC, Ricklin D, Papp K, Molnar KS, Coales SJ, Hamuro Y et al (2008) Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Mol Immunol 45(11):3142–3151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL et al (2010) Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255(2):517–526

    Article  PubMed  PubMed Central  Google Scholar 

  • Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM et al (2010) Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol 404(4):697–710

    Article  CAS  PubMed  Google Scholar 

  • Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P et al (2010) Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116(6):1002–1010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sirmaci A, Walsh T, Akay H, Spiliopoulos M, Sakalar YB, Hasanefendioglu-Bayrak A et al (2010) MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet 87(5):679–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Skattum L, Martensson U, Sjoholm AG (1997) Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med 242(6):455–464

    Article  CAS  PubMed  Google Scholar 

  • Skattum L, van Deuren M, van der Poll T, Truedsson L (2011) Complement deficiency states and associated infections. Mol Immunol 48(14):1643–1655

    Article  CAS  PubMed  Google Scholar 

  • Smith RA (2002) Targeting anticomplement agents. Biochem Soc Trans 30(Pt 6):1037–1041

    Article  CAS  PubMed  Google Scholar 

  • Smith GP, Smith RA (2001) Membrane-targeted complement inhibitors. Mol Immunol 38(2–3):249–255

    Article  CAS  PubMed  Google Scholar 

  • Sokolov A, Hellerud BC, Lambris JD, Johannessen EA, Mollnes TE (2011) Activation of polymorphonuclear leukocytes by candidate biomaterials for an implantable glucose sensor. J Diabetes Sci Technol 5(6):1490–1498

    Article  PubMed  PubMed Central  Google Scholar 

  • Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM (2005) APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 145(8):1027–1034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spitzer D, Unsinger J, Bessler M, Atkinson JP (2004) ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40(13):911–919

    Article  CAS  PubMed  Google Scholar 

  • Spitzer D, Unsinger J, Mao D, Wu X, Molina H, Atkinson JP (2005) In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. J Immunol 175(11):7763–7770

    Article  CAS  PubMed  Google Scholar 

  • Szalai AJ, Digerness SB, Agrawal A, Kearney JF, Bucy RP, Niwas S et al (2000) The Arthus reaction in rodents: species-specific requirement of complement. J Immunol 164(1):463–468

    Article  CAS  PubMed  Google Scholar 

  • Thorgersen EB, Ludviksen JK, Lambris JD, Sfyroera G, Nielsen EW, Mollnes TE (2010) Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immun 16(4):254–264

    Article  CAS  PubMed  Google Scholar 

  • Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K et al (2010) Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 78(2):152–159

    Article  CAS  PubMed  Google Scholar 

  • Tokodai K, Goto M, Inagaki A, Nakanishi W, Ogawa N, Satoh K et al (2010) Attenuation of cross-talk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation 90(12):1358–1365

    Article  CAS  PubMed  Google Scholar 

  • Torreira E, Tortajada A, Montes T, Rodriguez de Cordoba S, Llorca O (2009) 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA 106(3):882–887

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tourangeau LM, Zuraw BL (2011) The new era of C1-esterase inhibitor deficiency therapy. Curr Allergy Asthma Rep 11(5):345–351

    Article  CAS  PubMed  Google Scholar 

  • Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26(11):2085–2088

    Article  PubMed  Google Scholar 

  • van den Elsen JM, Isenman DE (2011) A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 332(6029):608–611

    Article  CAS  PubMed  Google Scholar 

  • van der Pals J, Koul S, Andersson P, Gotberg M, Ubachs JF, Kanski M et al (2010) Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord 10:45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Veerhuis R, Nielsen HM, Tenner AJ (2011) Complement in the brain. Mol Immunol 48(14):1592–1603

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vogel CW, Fritzinger DC (2010) Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 56(7):1198–1222

    Article  CAS  PubMed  Google Scholar 

  • Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26(1):41–57

    Article  PubMed  Google Scholar 

  • Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature 450(7172):1001–1009

    Article  CAS  PubMed  Google Scholar 

  • Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ et al (2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444(7116):217–220

    Article  CAS  PubMed  Google Scholar 

  • Woodruff TM, Nandakumar KS, Tedesco F (2011) Inhibiting the C5-C5a receptor axis. Mol Immunol 48(14): 1631–1642

    Article  CAS  PubMed  Google Scholar 

  • Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10(7):728–733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B et al (2011) Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J Immunol 186(7):4269–4277

    Article  CAS  PubMed  Google Scholar 

  • Yehoshua Z, Rosenfeld PJ, Albini TA (2011) Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin Ophthalmol 26(3):167–180

    Article  CAS  PubMed  Google Scholar 

  • Zeerleder S (2011) C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 37(4):362–374

    Article  CAS  PubMed  Google Scholar 

  • Zilow G, Sturm JA, Rother U, Kirschfink M (1990) Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 79(2):151–157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zipfel PF, Lauer NL, Ricklin D, Heinen SH, Dahse HMD, Tzekou A et al (2011) The new chimeric alternative complement inhibitor COMP_CFH15-20 protects surfaces from complement-mediated damage (conference abstract). Mol Immunol 48(14):1713

    Article  Google Scholar 

Download references

Acknowledgments

We thank Dr. Robert A. DeAngelis for critically reading the manuscript. This work was supported by National Institutes of Health grants AI068730, AI030040, AI072106, AI071028, AI097805, DE021685, GM97747, and EY020633.

Disclosure

J.D.L. is the inventor of the C3 inhibitor compstatin and holds several patents about the development and clinical application of compstatin analogs. He has previously served as a member on the Scienepsic Advisory Board of Potentia Pharmaceuticals and is the founder of Amyndas Biotherapeutics, which perform clinical development of compstatin analogs for various indications.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Pennsylvania, 401 Stellar Chance, 422 Curie Blvd, Philadelphia, PA, 19104-6100, USA

    Daniel Ricklin & John D. Lambris

Authors
  1. Daniel Ricklin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Lambris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Ricklin .

Editor information

Editors and Affiliations

  1. Medicine, University Of Pennsylvania Department Of Pathology Laboratory Of, Philadelphia, Pennsylvania, USA

    John D. Lambris

  2. University of Colorado School of Medicin, Aurora, Colorado, USA

    V. Michael Holers

  3. Department of Pathology & Laboratory Med, University of Pennsylvania School of Med, Philadelphia, Pennsylvania, USA

    Daniel Ricklin

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ricklin, D., Lambris, J.D. (2013). Progress and Trends in Complement Therapeutics. In: Lambris, J., Holers, V., Ricklin, D. (eds) Complement Therapeutics. Advances in Experimental Medicine and Biology, vol 735. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4118-2_1

Download citation

Publish with us

Policies and ethics

Search

Navigation